New combo therapy aims to outsmart tough hodgkin lymphoma
NCT ID NCT04134325
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase pilot study is testing whether giving a PD-1 inhibitor (nivolumab or pembrolizumab) after CAR-T cell therapy can help people with relapsed or refractory classical Hodgkin lymphoma. The trial plans to enroll 10 adults whose cancer has not responded to at least three prior treatments. The goal is to see if the combination can shrink tumors and improve immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nivolumab or Pembrolizumab (PD-1 inhibitors) after CD30-directed CAR-T cell therapy
What this could lead to
If successful, this approach could offer a new treatment option for patients with hard-to-treat Hodgkin lymphoma that has not responded to other therapies.
What could go wrong
This is a very early, small pilot study with only 10 participants. It may not show clear benefit, and results may not apply to all patients. Side effects from CAR-T and PD-1 inhibitors can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lineberger Comprehensive Cancer Center at University of North Carolina
Chapel Hill, North Carolina, 27599, United States